Evidence map›Paper›PMID 32692914›Full record

ArticleACS infectious diseases2020

Effects of Single α-to-β Residue Replacements on Recognition of an Extended Segment in a Viral Fusion Protein.

Victor K Outlaw, Dale F Kreitler, Debora Stelitano, Matteo Porotto, Anne Moscona, Samuel H Gellman

Open access · greenAbstract read
In one paragraph

Article in ACS infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Antivirals targeting paramyxovirus membrane fusion.Current opinion in virology · 2021
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Victor K OutlawDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin 53706, United States.ORCID 0000-0001-7054-4204
Dale F KreitlerDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin 53706, United States.
Debora StelitanoDepartment of Pediatrics, Columbia University Medical Center, New York, New York 10032, United States.
Matteo PorottoDepartment of Pediatrics, Columbia University Medical Center, New York, New York 10032, United States.
Anne MosconaDepartment of Pediatrics, Columbia University Medical Center, New York, New York 10032, United States.
Samuel H GellmanDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin 53706, United States.ORCID 0000-0001-5617-0058
University of Wisconsin–Madison · USUniversity of Campania "Luigi Vanvitelli" · ITColumbia University Irving Medical Center · US

Funding

BIOTECHNOLOGY TRAINING PROGRAMT32GM008349 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI FOX, BRIAN G · 1989 to 2019
$22.5M
Use of designed peptides to study folding and bindingR01GM061238 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI GELLMAN, SAMUEL H. · 2000 to 2023
$7.9M
Engineering protease-resistant alpha-beta peptides for broad-spectrum antiviralsR01AI114736 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCONA, ANNE · 2015 to 2019
$3.7M
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agentsR01AI121349 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO · 2016 to 2020
$3.2M
Structure-Guided Design of Peptidomimetic Inhibitors of Paramyxoviral FusionF32GM122263 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI OUTLAW, VICTOR KENNETH · 2017 to 2017
$57k
NIAID NIH HHS R01 AI114736NIAID NIH HHS R01 AI121349NIGMS NIH HHS F32 GM122263NIGMS NIH HHS R01 GM061238NIGMS NIH HHS T32 GM008349
6 · The paper itself

Abstract

Partial replacement of α-amino acid residues with β-amino acid residues has been established as a strategy for preserving target-engagement by helix-forming polypeptides while altering other properties. The impact of β-residue incorporation within polypeptides that adopt less regular conformations, however, has received less attention. The C-terminal heptad repeat (HRC) domains of fusion glycoproteins from pathogenic paramyxoviruses contain a segment that must adopt an extended conformation in order to coassemble with the N-terminal heptad repeat (HRN) domain in the postfusion state and drive a merger of the viral envelope with a target cell membrane. Here, we examine the impact of single α-to-β substitutions within this extended N-terminal segment of an engineered HRC peptide designated VIQKI. Stabilities of hexameric coassemblies formed with the native human parainfluenza virus 3 (HPIV3) HRN have been evaluated, the structures of five coassemblies have been determined, and antiviral efficacies have been measured. Many sites within the extended segment show functional tolerance of α-to-β substitution. These results offer a basis for future development of paramyxovirus infection inhibitors with novel biological activity profiles, possibly including resistance to proteolysis.

Indexed as

Viral Fusion ProteinsVirus InternalizationAntiviral AgentsHumansParainfluenza Virus 3, HumanPeptidesAntiviral AgentsPeptidesViral Fusion Proteinsentry inhibitorfusion glycoproteinHPIV3viral entryα/β-peptideβ-amino acid

Identifiers

PMID32692914
PMCPMC8019249
OpenAlexW3044327343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.